SCHEMBL13627904

SCHEMBL13627904

O=C1/C(=N\O)c2cc(Br)ccc2N1Cc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.53
CA1 P00915 4/20 0.52
CA2 P00918 4/20 0.52
CA12 O43570 3/20 0.52
CA9 Q16790 3/20 0.52
ALDH1A1 P00352 6/20 0.50
MAPT P10636 3/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
LMNA P02545 1/20 0.50
HPGD P15428 1/20 0.50
HTT P42858 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
UCHL1 P09936 1/20 0.50
UCHL3 P15374 1/20 0.50
CASP1 P29466 1/20 0.50
CASP3 P42574 1/20 0.50
CASP4 P49662 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627920 0.86 MAPT (0.52) ACHECA1CA2CA12CA9
SCHEMBL13627938 0.86 CA12 (0.52) CA1CA2CA12CA9ALDH1A1
SCHEMBL13627887 0.85 MAPT (0.66) ACHECA1CA2CA12CA9
SCHEMBL13627912 0.84 MAPT (0.57) ACHECA1CA2CA12CA9
SCHEMBL13627911 0.84 CASP3 (0.56) CA1CA2CA12CA9ALDH1A1
SCHEMBL13627910 0.84 CASP1 (0.72) ACHECA1CA2CA12CA9
SCHEMBL13627901 0.83 ACHE (0.58) ACHECA1CA2CA12CA9
SCHEMBL13627905 0.83 ACHE (0.60) ACHECA1CA2CA12CA9
SCHEMBL13627895 0.83 MAPT (0.58) CA1CA2CA12CA9ALDH1A1
SCHEMBL13627900 0.83 ALDH1A1 (0.69) ACHECA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ACHE 4079/4885CA1 3628/4885CA2 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.